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Sarcopeniaisaconditionofmultifacetedetiologyarisinginmanyelderlypeople.Inpatientswithchronickidney,thelossofmuscle
mass is much more intensive and the ﬁrst signs of sarcopenia are observed in younger patients than it is expected. It is associated
with the whole-body protein-energy deﬁciency called protein-energy wasting (PEW). It seems to be one of the major factors
limiting patient’s autonomy as well as decreasing the quality of life. If it cannot be treated with the simple methods requiring
some knowledge and devotion, we will fail to save patients who die due to cardiovascular disease and infection, despite proper
conduction of renal replacement therapy. Many factors inﬂuencing the risk of sarcopenia development have been evaluated in
number of studies. Many studies also were conducted to assess the eﬃcacy of diﬀerent therapeutic strategies (diet, physical activity,
hormones). Nevertheless, there is still no consensus on treatment the patients with PEW. Therefore, in the paper we present the
reasons and pathophysiology of sarcopenia as an important element of protein energy wasting (PEW) in elderly patients suﬀering
from chronic kidney disease. We also analyze possible options for treatment according to up-to-date knowledge.
1.Introduction
The development of dialysis and the increasing availability
of this renal replacement therapy method is the reason
elderlypatientshavebecomeagrowingpopulationindialysis
centers. The average age of hemodialyzed patients in many
countries exceeds 60 years. Sarcopenia is a condition arising
in many elderly people mainly as a result of reduced physical
activity, although a lot of data suggests a multifaceted etiol-
ogy of the phenomenon. An adult without chronic kidney
disease should expect a loss of muscle mass reaching 1% per
year [1, 2]. Very often it can be reduced through appropriate
physical training [3].
Patients with chronic kidney disease experience probably
the same age-related processes. It is interesting, however,
that in those patients the loss of muscle mass is much more
intensive. Moreover, the ﬁrst signs of sarcopenia in CKD
patients are observed earlier compared to their peers. It is
very well marked in patients with the end-stage renal disease
(ESRD or CKD V according to K/DOQI guidelines), who are
treated with various methods of renal replacement therapy.
The most signiﬁcant aberrations have been recorded in pa-
tients treated with hemodialysis.
The question is, what factors can inﬂuence such situation
and whether sarcopenia developing in healthy people over 60
yearsoldhasthesamepathogenicbasisastheonedeveloping
in CKD patients.
Many authors have studied the phenomenon of muscle
wasting. According to the International Society of Renal Nu-
trition and Metabolism (ISRNM), it is a signiﬁcant element
of the condition deﬁned as protein-energy wasting (PEW). It
describes the organism’s state of reduced protein and energy
resources. It is assumed that 18–75% of patients with CKD
suﬀers from PEW [4–6].
According to the ISRNM statement, there are 4 main cri-
teria useful in PEW diagnosis:
(1) low body weight, reduced body fat and weight loss,
(2) reduced muscle mass judged on the basis of mid-
arm circumference, dual X-ray absorptiometry, near-
infrared interactance, bioelectrical impedance, or
creatinine appearance,2 Journal of Aging Research
(3) low protein/energy intake,
(4) biochemical indicators [7].
BMI is one of the methods to assess low body weight,
although in patients with ESRD it might be inappropriate,
becauseofﬂuidimbalance[8,9].Someoftheauthorssuggest
subjective global assessment (SGA), as a precise marker of
body weight loss. Undisputedly, it is more complicated, as it
requiresnotonlyasimplemathematicoperationbutisbased
on medical history and physical examination. Stenvinkel
et al. proved that it might be useful in assessment of ESRD
patient outcome as SGA ≥ 2 is correlated signiﬁcantly with
increased cardiovascular mortality [10].
Unintentionalweightlossofatleast5%ofbodyweightin
3 months or ≥10% in 6 months is another (independent of
BMI) indicator of PEW. In patients with CKD, body fat mass
less than 10% may also be pathognomonic for PEW [11].
Reduced muscle mass seems to be the most important
element of PEW. Mid-arm circumference is a simple, but
precisemethodofmusclelossassessment.Noorietal.proved
it is correlated with the survival and quality of life in patients
on hemodialysis [12]. All other—mentioned above—meth-
ods are not widely used, because of their limitations (partic-
ularly concerning water imbalance) in ESRD [13]. Only cre-
atinine appearance (assessed by quantiﬁcation of creatinine
in 24h urine collection and in the collected spent dialysate)
is useful, but labor-consuming method [14].
Both low protein/energy intake and anorexia are associ-
atedwithhighcardiovascularrisk.Infact,anorexiaisasevere
formoflowprotein/energyintake,veryoftenconnectedwith
cachexia. In many cases, it is associated with high concen-
trations of proinﬂammatory factors and ESA resistance lead-
ing to low quality of life and increased mortality [15]. Un-
intentional dietary energy intake (DEI) lower than 25kcal/
kg/day for at least 2 months or unintentional dietary protein
intake (DPI) lower than 0.8g/kg/day forat least 2 months are
criteria for low protein/energy intake [7].
Serum albumin is the most important biochemical indi-
cator of PEW in patients on maintenance dialysis. It should
be controlled regularly, as serum albumin still remains the
most readily available PEW indicator with very high sensi-




vascular risk factors (obesity, diabetes, smoking, hyperten-
sion, dyslipidemia) [16–19].
Low serum prealbumin concentration is another good
PEW indicator in patients on maintenance dialysis. It was
proved, that the concentration below 20mg/dL or a fall in
serum prealbumin over 6 months is an independent risk fac-
torfordeath,evenwhenthealbuminlevelremainsinnormal
range [20, 21]. Rambod et al. have made an interesting ﬁnd-
ing according prealbumin, which might turn into an option,
when it comes to sarcopenia treatment. They found the pos-
itive correlation between serum prealbumin concentration
and percentage muscle mass, as well as inverse association
between serum prealbumin and percentage body fat [21].
Transferrin serum level as well as serum cholesterol
(<100mg/dL) may also serve as protein energy wasting in-
dicators [22, 23].
The interest in the phenomenon of protein and energy
loss seems to be obvious when we realize what important
consequences result therefrom. First of all, it is one of the
main predictors of mortality in patients with ESRD [1, 10,
24]. It also causes a signiﬁcant reduction in quality of life.
Loss of lean body mass may lead to frequent falls, osteo-
porosis, and its complications, thus limits the autonomy of
patients and may be a cause of disability [25]. Besides the
protein degradation, the accompanying fat accumulation in
the visceral area favors the development of insulin resistance
and, consequently, the metabolic syndrome and many of its
consequences [25].
1.1. What Happens to the Protein and to the Skeletal Muscles
inESRDPatients? Manyauthorshaveevaluatedthedegrada-
tion of skeletal muscle protein in their studies trying to link
the observed phenomena with the metabolic state of the
organism. During hemodialysis, we observe enhanced prote-
olysis in muscle. It should be noted that about 10g of amino
acidsareirreversiblylosttothedialysateduringhemodialysis
[26]. It may cause a loss of muscle mass exceeding 1% per
year. Amino acids infusion though in the study of Raj did
not bring expected results of muscle regeneration [26].
An unrecognized steering mechanism causes the prod-
ucts of muscle protein breakdown which are released to the
blood and transported to the liver, where they serve probably
as substrates for acute phase proteins synthesis [26–28]. The
hypothesis could explain the inﬂammatory system activation
in CKD patients.
Notonlytheproteinlossandnotjustreductionofmuscle
mass aﬀect the patients’ functioning, however. Another neg-
ative phenomenon is the change of the quality of the muscu-
larcompartment.InpatientswithESRD,weobserveboththe
accumulation of fat in the striated muscle cells (intramus-
cular lipid) and in the form of intermuscular adipose tissue
(IMAT), subfascially [1].
Inthestudywith49hemodialyzedpatients,Cheemaetal.
demonstrated that such disturbed muscle structure is more
common in older people, with hypoalbuminaemia and high
levels of proinﬂammatory cytokines. IMAT was associated
particularly with high BMI and larger waist circumference.
The researchers pointed out that this inﬂuenced the func-
tioning of patients with statistically signiﬁcant reduction of
physical ﬁtness, which was conﬁrmed by objective methods
(reduced gait velocity, decreased 6-minute walking distance,
peak isometric strength) [1]. Honda et al. examining obese
(BMI > 30) patients with ESRD found a severe expression of
inﬂammation markers, which was probably derived from the
adipose tissue [29].
2.The Mechanismsofthe Sarcopenia
Development in Elderly Patients with
ChronicKidney Disease
Global dialysis development brought us the possibility of















Causes of sarcopenia in chronic kidney disease
Figure 1: Causes of sarcopenia in chronic kidney disease patients.
of course, the anatomical and functional assessment of the
muscular system. Many reports have described the mecha-
nisms of muscle tissue destruction.
The current state of knowledge indicates that the factors
predisposing patients with chronic kidney disease to the
development of sarcopenia in fact can be divided into two
groups (Figure 1):
(1) associated with the kidney disease (nutritional deﬁ-
ciencies, development of acidosis, vitamin D deﬁ-




particularly characteristic for hemodialysis patients,
but also observed in patients not enrolled in the
chronic dialysis [26, 29].
2.1. Factors Associated with Chronic Kidney Disease Con-
tributing to the Development of Sarcopenia. Nutritional deﬁ-
ciencies seem to be the most important reason of muscle
loss in ESRD patients. Besides socioeconomical causes (very
signiﬁcant in many countries) leading to malnutrition, there
are some other bases for inadequate protein/energy intake.
Altered taste, gastroesophageal reﬂux, and impaired gastric
emptying (particularly in patients with diabetic gastropare-
sis) are the most common. The phenomenon is potentiated
by depression development, quite frequent in patients with
chronic diseases. It leads not only to low protein/energy in-
take, but also may promote proinﬂammatory status. Bellisle
et al. and Hung et al. found the association between de-
pression and high IL-6 serum concentration, which was
correlated with low serum albumin level [30, 31].
In patients with ESRD, inadequate nutrition is also a
consequence of leptin and ghrelin perturbation. In a healthy
human,kidneyistheplaceofthetwohormonesdegradation.
With decreasing GFR, the metabolism of ghrelin and leptin
becomes insuﬃcient. Increased concentration of proinﬂam-
matory cytokines also contributes to leptin accumulation
[32, 33].
The data concerning leptin inﬂuence on PEW remain
conﬂicting, although some experimental data bring some
hopeforfuturetreatment.Cheungetal.intheirstudyproved
that leptin signaling through hypothalamic melanocortin-
4 receptor blockade leads to cachexia amelioration in mice.
The authors pointed, that it could be only one of many
pathways,assomeindicatorsofexcessivemuscledegradation
remained high during the study [34].
The role of ghrelin in ESRD-PEW development remains
uncertain. There are two major forms of circulating ghrelin:
acylatedghrelinanddes-acylghrelin.Thelatterisresponsible
for negative energy balance and that form is probably as-
sociated with low protein/energy intake [35]. Nevertheless,
the role of ghrelin in PEW development requires further
investigation.
Metabolic acidosis inevitably accompanying chronic kid-
ney disease, especially in its advanced stages (when it
comes to glomerular ﬁltration rate reduction below 25mL/
min/1.73m2), is one of the most common reasons of PEW
[36–38]. Its multifaceted impact on muscle in patients
with chronic kidney disease is via impairment of albumin
synthesis,increasedproteinandbranched-chainaminoacids
degradation, and increased proinﬂammatory cytokine syn-
thesis. [38]. It is been postulated recently, that the main rea-
sonforsarcopeniasecondarytometabolicacidosisisincreas-
ing insulin resistance [39]. Oral bicarbonate therapy, as it
is advised in patients with GFR below 30/mL/min/1.73m2
might reduce the impact of these metabolic disorders [38].
It proved to be eﬃcient in insulin resistance improvement,
probably by enhanced synthesis of 1,25(OH)2D3 [40].
Insulin resistance has appeared as one of the most
important metabolic challenges in patients with CKD [41].
Diabetes is an independent risk factor for muscle wasting
in patients with ESRD [26, 42]. Pupim et al. proved that in
patients with ESRD, the loss in lean body mass was signif-
icantly increased in those who suﬀered from diabetes [42,
43]. The possible mechanisms are the concomitant insulin
resistance, the intensity of inﬂammatory processes, and,
sometimes, massive loss of protein in the urine [44]. Type 2
diabetes is the most common cause of chronic kidney disease4 Journal of Aging Research
observed in hemodialysis patients. Therefore, it seems that
reducing the impact of accompanying metabolic disorders
on the muscle may signiﬁcantly result in survival improve-
ment and better quality of life in the dialysis patient popula-
tion.
Insulin resistance is observed also in nondiabetic and
nonobese patients on maintenance dialysis. It is associated
with increased muscle protein breakdown mainly mediated
by ubiquitin-proteasome pathway (described below) [45]. It
was also proved that insulin resistance leads to decrease in
muscle PI3K (phosphatidylinositol 3 kinase), which is the
reason for high ubiquitin-proteasome system activity, but
also a reason for Bax-dependent caspase-3 hyperactivity
leading to enhanced protein degradation. Some data suggest
that peroxisome proliferator-activated receptor (PPAR) ago-
nists (thiazolidinediones) may reverse this mechanism [46,
47].
Themoreeﬀectivetreatmentofsecondaryhyperparathy-
roidism in chronic kidney disease is probably the reason
the calcium-phosphate metabolism disturbances are not the
mainprobleminthedevelopmentofsarcopenia.Thereisstill
a phenomenon of muscle weakness (mainly proximal muscle
groups) in patients with uncontrolled hyperparathyroidism.
Moreover, some authors treat myopathy as an indication for
parathyroidectomy [48, 49]. Now it seems that the optimi-
zation of dialysis, the appropriate pharmacological action, in
theabsenceofparathyroidadenoma(whichshouldalwaysbe
ruled out), may help to prevent muscular complications.
Vitamin D deﬁciency associated with renal failure also
contributestothedevelopmentofmyopathy,mainlythrough
increasing insulin resistance [50, 51]. In 1980, Norman et al.
showed that vitamin D deﬁciency aﬀects insulin secretion by
pancreatic islet β-cells [52], and few years later they proved
beneﬁcial eﬀects of vitamin D supply on glucose tolerance
and decreased insulin resistance [53]. This was conﬁrmed
also in chronic kidney disease [54].
In some patients, proteinuria in the course of primary
kidney disease may lead to signiﬁcant protein losses. It may
be an important reason in patients with earlier stages of
chronic kidney disease. During hemodialysis, with decreas-
ing residual diuresis, this way of protein loss becomes less
important.
2.2. Chronic Kidney Disease and Activation of Inﬂammatory
Reaction. The fact that chronic kidney disease is a state of
permanent inﬂammatory process has been known for many
years [1, 26, 55, 56]. Cytokine signaling through nuclear fac-
tor kappaB (NFκB) results in a stimulation of enzymatic
systems (described below) favoring muscle proteolysis [26,
55]. TNFα,I L - 6 ,I L - 8 ,a n dI F N - γ are mentioned among
the most frequently observed indicators and stimulators of
muscle proteolysis, while C-reactive protein (CRP) seems to
be a useful and inexpensive, although nonspeciﬁc, marker of
systemic inﬂammation [4, 57]. Metabolic acidosis, hormo-
nal disorders (mainly related to the accumulation of adipose
tissue hormones—leptin and adiponectin, and ghrelin deﬁ-
ciency), and blood contact with synthetic dialysis mem-
branes in hemodialysis patients are the known factors in-
creasingthesynthesisofproinﬂammatorycytokines[57–59].
The main sources of inﬂammatory cytokines are activated
lymphocytes and macrophages, adipose tissue, and the skel-
etal muscles themselves [26]. It is assumed that persistent
inﬂammation causes abnormal utilization of amino acids
administered during hemodialysis. They are not built into
the muscles, as we would expect during muscle reconstruc-
tionafterproteolysis.Aminoacidsaretransportedtotheliver
where they are utilized probably to the synthesis of acute
phase proteins [7, 60]. Experimental attempts to block TNFα
and NFκB inhibited skeletal muscle proteolysis [61, 62].
Permanent inﬂammation promotes oxidative stress, and
thus the formation of oxygen free radicals. That is another
factor exacerbating inﬂammatory response by aﬀecting
NFκB especially with impaired mitochondrial function and
reducedantioxidantcapacity.Itisobviousthatinﬂammatory
activation and oxidative stress are not only harmful to the
kidneys of patients with chronic kidney disease, but also af-
fect the cardiovascular system, therefore, contribute to the
premature death of patients with chronic kidney disease
[4, 44].
Chronicinﬂammationpromotesreducedmusclemassby
inhibiting insulin signaling and increasing energy expendi-
ture, which cannot be covered by appropriate energy intake
in ESRD patients. Increase energy expenditure in terms
of inadequate energy intake is a characteristic feature of
PEW. Besides activation of proinﬂammatory processes, also
increased activity of mitochondrial anion transporters-
uncoupling proteins (UCP) may lead to increased resting
metabolic rate. UCP-1 and UCP-3 seem to be key regulators
of energy expenditure in humans [63–65]. Cheung et al.
proved both proteins are expressed intensively in uremic
mice[34].Uncouplingofmitochondrialelectrontransporter
chain activity from the ADP phosphorylation leads to en-
hanced thermogenesis and subsequently high-energy expen-
diture [64].
2.3. Molecular Mechanisms of Muscle Proteolysis in Chronic
Kidney Disease. Three main systems are involved in the deg-
radation of muscle proteins: the cytosolic calcium dependent
calpain system, the lysosomal proteases (cathepsin system),
and ubiquitin-proteasome system (UPS) [26, 58]. The avail-
able studies show the ﬁrst two systems are not very active in
terms of increased catabolism, and their inhibition does not
contribute to proteolysis suppression [58, 66]. Therefore, the




followed by its transfer to an ubiquitin-conjugating enzyme
(E2). E2transferstheactivatedubiquitin moieties tothepro-
tein substrate that is bound speciﬁcally to a unique ubiquitin
ligase E3. Successive conjugation of ubiquitin moieties to
one another generates a polyubiquitin chain (containing 5
ubiquitin moieties) that serves as the binding signal for the
26S proteasome degrading the target substrates to peptides
[41, 58] (Figure 2). Peptides are than hydrolyzed to amino
acids by peptidases in cytoplasm.
Impaired insulin/IGF-I signaling is another pathway










Figure 2: Ubiquitin-proteasome system. U: ubiquitin, AU: activated ubiquitin, E1: ubiquitin-activating enzyme, E2: ubiquitin-conjugating
enzyme, E3: ubiquitin ligase.
stimulation is most commonly caused by metabolic acidosis,
elevated angiotensin II, and chronic inﬂammation. Inhibit-
ing of Act phosphorylation leads to Caspase-3 activation and
thus to severe proteolysis. The reduction of a forkhead tran-
scription factor (FOXO) phosphorylation is another eﬀect
of impaired IGF-I receptor stimulation. In such conditions,
FOXO is transited to the cell nucleus and stimulates the syn-
thesis atrogin-1/muscle atrophy f-box (MAFbx) and Muscle
ring ﬁnger 1 protein (MuRF1). They belong to a group of
UPS E3 enzymes that recognize speciﬁc muscle proteins,
leading to their degradation [58, 68]. An intensive MuRF1
expression is also the reason for hypercortisolaemia-induced
myopathy [69].
Myostatin is another protein having its negative impact
on the development of sarcopenia in patients with chronic
kidney disease. Its role is to block the expression of MyoD
that enhances myogenesis. Sun et al. have demonstrated in-
creased expression of myostatin in the muscle of rats with
end-stage renal disease. They also indicate at the imbalance
between myostatin and IGF-I as one of the mechanisms
responsible for muscle atrophy in chronic kidney disease
[70].
3. Methods of SarcopeniaPreventionand
Treatment in Elderly Patients with Chronic
Kidney Disease—CouldIt Be Effective?
Based on the above-cited advances in understanding the
mechanisms causing sarcopenia, several studies were de-
signed to propose some treatment and improve patients’
survival and their quality of life.
3.1. Physical Activity and Nutrition. It seems that the im-
plementationofappropriatetraininginpatientswithchronic
kidney disease both in predialysis period as well as during
dialysis can reduce the risk of sarcopenia. This action also
modulates the risk of cardiovascular diseases—the leading
cause of death in patients with ESRD. Therefore, it is
a strongly recommended strategy to implement in CKD pa-
tients both young and elderly. Storer et al. proved that
endurance exercise might improve strength, power, and
physical performance in haemodialysis patients [71]. Prob-
able mechanisms include improved insulin sensitivity, de-
creased synthesis of pro-inﬂammatory cytokines, improved
conduction through the IGF-I, and thus also UPS pathway
depression. Storer et al. have conﬁrmed the hypothesis of the
inﬂammatory response inhibition in the studies, where the
CRP and IL-6 concentrations were diminished as a result of
twelve-week resistance training in patients on dialysis [71].
Smart and Steele observed a reduction of TNFα synthesis in
their meta-analysis concerning patients with chronic heart
failure, in whom physical therapies employing ≥5 sessions
per week were introduced [72].
Cheema et al. studied an impact of 12-week progressive
resistance training (PRT) administered during hemodialysis
on skeletal muscle quantity and quality. They showed that
PRT is not suﬃcient in LBM improvement but proved a
statistically signiﬁcant improvement in muscle strength, at-
tenuation, mid-arm, and mid-thigh circumference compar-
ing to group treated in a usual way [73].
Johansen et al. in their study with anabolic steroid ad-
ministration and resistance training proved there was an in-
creaseinquadricepscross-sectionalarea.Unfortunately,they
did not notice any increase in lean body mass in the group of
patients, where exercise was the only therapeutical method.
Nevertheless, their study showed some improvement in self-
reported physical functioning [74]. The study by Kopple et
al. revealed a slight increase in lean body mass assessed by
dual-energy X-ray absorptiometry. It was correlated with
upregulation of mRNA and protein of IGF-I in skeletal
muscles [75].
According to our best knowledge in 29 clinical trials,
the aerobic training improved patients’ physical condition
(by increasing exercise capacity and exercise duration) [76].
Resistance training was beneﬁcial for patient muscle strength
and their functional capacity (increase in the peak torque of
quadriceps muscle, improved walking-distance in a 6-min6 Journal of Aging Research
walk test, improved walking speed, and improved perfor-
mance in a sit-to-stand test) [77].
In a number of studies, the beneﬁcial eﬀects of both
aerobicandresistancetrainingwereproved.Deligiannisetal.
showed that aerobic physical training leads to improved car-
diac function measured by ejection fraction, cardiac output
index, and systolic volume index [78]. Kouidi described also
an increase in cardiac vagal activity, diminished sympathetic
hyperactivity, and less incidence of arrhythmias in CKD
patients treated with appropriate physical activity [79].
Physical activity also seems to have an inﬂuence on arte-
rial hypertension control both—during hemodialysis and in
the interdialytic period [80–82]. It is important to continue
the treatment, as Boyce et al. noticed, that after 2 months of
exercise cessation high values of systolic and diastolic treat-
ment returned [83], probably due to increasing arteries stiﬀ-
ness [84].
Intermsofmetabolicchangescausedbyphysicalactivity,
decreased concentration of VLDL and triglycerides com-
bined with improved level of HDL was proved by Goldberg
et al. [85] The knowledge of improved insulin resistance in
physicallyactive patients is common and has been conﬁrmed
in the number of trials [86].
Parsons et al. and Oh-Park et al. proved that adequate
physical activity may improve hemodialysis eﬃciency. The
probable reason for such situation is increased muscle per-
fusion, which occurs during exercise. It leads to the transfer
of uremic toxins concentrated in muscles to the circulation;
therefore, they can be easily removed during hemodialysis. A
so-called“post-dialysisrebound”(increasedurea,creatinine,
potassium after hemodialysis due to the slow transfer from
poorly perfused regions, i.e., skeletal muscles) is diminished
in physically active patients [87–89].
Some authors concentrated their eﬀorts on proving a
beneﬁcial eﬀect of exercise during hemodialysis on skeletal
muscle ﬁbers. A resistance training leads to reduction of
atrophic ﬁbers number, an increase in type I, type IIa, and
type IIx muscle ﬁbre cross-sectional areas. [90]. Also aerobic
training in CKD patients may lead to such changes in muscle
structure, which is not typical in general population. Prob-
ably the large potential for skeletal muscle improvement in
CKD patients is the reason for this phenomenon [91].
T h eg r e a tv a l u eo fp h y s i c a le x e r c i s ef o ri m p r o v e dp s y -
chological adaptation also has been researched. Kouidi et al.
showed that Beck’s Depression Index was decreased in pa-
tients physically active, which was conﬁrmed in the Ouzouni
et al. research [92, 93]. In the studies of Oh-Park et al. and
Painter et al. the mental health and health-related quality
of life (HRQoL) improvement assessed on the basis of SF-
36 QoL scale was presented, although the evidence remains
moderate due to lack of statistical signiﬁcance [88, 94].
Cheemaetal.provedastatisticallysigniﬁcantpositiveimpact
of resistance training on HRQoL (also using SF-36 QoL
scale) [73]. As depression is one of the reasons for low pro-
tein/energy intake, some authors also proved an increase in
appetite (and subsequently DEI and DPI) [95].
As inadequate protein/energy intake and high energy
expenditure are characteristic features of PEW, a proper
nutrition seems to be a natural treatment option to choose
in patients on maintenance dialysis. Up to date, the inﬂuence
of nutritional therapy in ESRD patients was researched in 13
randomizedtrials.Theresultsofthemostimportantonesare
presented in Table 1 [96–104]. Most of them were performed
on small groups of patients, which make any analysis con-
cerning sarcopenia treatment diﬃcult. The combination of
a proper nutrition with exercise, nevertheless, might be an
eﬃcient treatment option [105, 106]. Cheung et al. using a
mouse model of CKD proved, however, that nutritional sup-
plementation may contribute to wasting improvement and
decreasing metabolic rate in CKD, butit will not fullycorrect
them [34, 107]. As it was mentioned earlier, attempts to sup-
ply amino acids during dialysis did not produce the expected
results [26].
The eﬀect of appetite-stimulating agent, megestrol ac-
etate, is still not enough documented in randomized con-
trolled trials in large groups of the patients. In the studies
designed by Boccanfuso and Burrowes on a small group of
patients with ESRD, the risk of adverse events exceeded the
b e n e ﬁ t so fm e g e s t r o lu s e[ 108, 109]. They noticed no signiﬁ-
cant increase in LBM, but reported many side-eﬀects instead
(headache, dizziness, confusion, diarrhea, hyperglycemia,
thromboembolism, peripheral edema, hypertension, and
adrenal insuﬃciency). Some recent studies, although, have
proved megestrol acetate has a beneﬁcial eﬀect not only
according to the nutrition status, but also improving inﬂam-
matory parameters [110, 111].
3.2. Hormone Therapy. Some very promising data from
studies with recombinant human Growth Hormone (rhGH)
has been published so far. Pupim et al. observed its beneﬁcial
anabolic eﬀect in hemodialysis patients in the short-term
therapy [112]. The increase in muscle protein synthesis was
proved by Garibotto et al. who administered 50ug of rhGH
for 6 weeks in patients with cachexia and ESRD [113]. Feldt-
Rasmussen et al. proved beneﬁcial eﬀect of rhGH on LBM
and quality of life in patients with ESRD. What is very
important is that they did not notice any signiﬁcant side
eﬀects [114]. Still more controlled trials are required to eval-
uate the eﬀect of rhGH therapy both in predialysis and
dialysis patients.
Wynne et al. and Ashby et al. assessed ghrelin subcu-
taneous injection in patients with ESRD, but the results
proved only some improvement in short-term energy intake
[115, 116]. There are no trials concerning possible ghrelin
administration eﬀect on muscle metabolism.
Cheung et al. demonstrated an important role of leptin
in PEW development. They also proved that the blockade
of melanocortin receptor 4 (MC4-R), by AgRP or NBI-12i,
attenuated uremic cachexia in mice [34, 107]. As an eﬀect of
the therapy, the mice gained lean body mass and fat mass
in comparison to the control group treated only with an
appriopriate diet. Their basal metabolic rate was decreased,
which shows that some other studies concerning leptin and
melanocortin signaling pathway are necessary to expand and
enhance the treatment arsenal.
3.3.UPSSuppression. UPSisoneofthecentralpathwaysthat
contribute to muscle breakdown. It seems that the currentJournal of Aging Research 7
Table 1: Review of the most important randomized controlled trials concerning nutrition treatment in ESRD patients.
Author Implemented treatment N Results
Sundell et al. [96] Pro-Stat 64 administered during hemodialysis 6
(i) Increased essential, nonessential, and total plasma
amino acids concentration.
(ii) Whole-body protein breakdown and net protein
balance became statistically signiﬁcantly better during
HD in a dose-dependent manner.
Allman et al. [97] Polycose-glucose polymer 9
(i) A mean increase in body fat of 1.8kg and the lean
body mass increased by 1.3kg.
(ii) The weight gain maintained after 6 months.
Milano et al. [98]G l u c o s e p o l y m e r 2 7
(i) Increase in body weight, body mass index, triceps
skinfold, and brachial circumference at the end of the
third month.
(ii) Results were conﬁrmed at 6 months in 18 patients
that completed the study (mean body weight
gain—2.4kg).
(iii) The nutritional status improved in only 4 patients at
the end of the study.
Kuhlmann et al. [99]
Dietary treatment—3 groups: A: 45kcal/kg/d and
1.5g protein/kg/d; B: 35kcal/kg/d and 1.2g
protein/kg/d; C: spontaneous intake supplemented
with 10% of mean protein and energy intake
18
(i) Weight gain (1.2 ±0.4kg) observed only in group A.
(ii) Serum albumin levels increased by 1.0 ±0.5g/L only
in group A.
Patel et al. [100] Dietary supplements 17
(i) Dietary supplements signiﬁcantly increased both the
nPCR and the total protein intake at 2 months and after
8m o n t h s .
(ii) No change in the nutritional status of the subjects.
Hiroshige et al. [101] Oral branched-chain amino acids (BCAAs)
supplementation (12g/day) 28
(i) Anorexia and poor oral protein and caloric intakes
improved.
(ii) The improvement in plasma BCAA levels.
(iii) Increase and mean plasma albumin concentration.
Leon et al. [102]
Identiﬁcation and intervention on nutritional
barriers (depression, poor knowledge, poor
appetite, help with shopping or cooking, low ﬂuid
intake, inadequate dialysis dose, depression,
diﬃculty chewing, diﬃculty swallowing,
gastrointestinal symptoms, and acidosis)
180
(i) Intervention patients had greater increases in albu-
min levels compared with control patients after 1 year.
(ii) Greater increases in energy intake and protein intake
in the intervention patients.
(iii) The intervention most eﬀective for barriers related
to poor nutritional knowledge, help needed with
shopping or cooking, and diﬃculty swallowing.
Fouque et al. [103] Renilon 7.5(R) daily for 3 months 86
(i) Increased DPI and DEI compared to control group.
(ii) No diﬀerence in serum albumin and prealbumin
changes between groups.
(iii) Improved SGA and QOL
Caglar et al. [104] Oral nutritional supplement speciﬁcally
formulated for CHD patients 85
(i) Signiﬁcant increases in concentrations of serum
albumin and serum prealbumin.
(ii) SGA score increased 14% by the end of the study.
therapy proposals should be directed to modiﬁcation of this
system. Bortezomib—now used in cancer therapy protea-
some inhibitor—can aﬀect the UPS system by inhibiting
NFκB signalling [117]; however, possible implementation of
such treatment requires further investigation.
3.4. Optimizing Hemodialysis. Hemodialysis patients are
particularly vulnerable to the development of sarcopenia,
mainly due to strong stimulation of the inﬂammatory re-
sponse during hemodialysis. Attempts have been made,
therefore, to shorten the exposure of blood to the dialysator
membranes by reducing the time of hemodialysis, in ex-
change for increasing their frequency. Galland et al. observed
ab e n e ﬁ c i a le ﬀect of such proceedings in 2 studies, with the
increase in lean body mass, serum albumin, prealbumin,
and cholesterol concentration during the 6- and 12-month
followup [118, 119]. The studies, however, were conducted
on small groups of patients (n = 8, n = 17), although one
should appreciate the relatively long observation period.
Similar observations have never been conﬁrmed in a large
patient population.
3.5. Treatment of Acid-Base and Calcium-Phosphate Metab-
olism Disorders. An active form of vitamin D3 deﬁciency
characterizes chronic kidney disease. Its supplementation
may result in a reduction of insulin resistance and reduced
activity of the UPS. Mak conducted a study with only in-
travenous use of vitamin D3. Intravenous 1,25(OH)2D38 Journal of Aging Research
therapy corrected glucose intolerance, insulin resistance, and
hypoinsulinemia as well as hypertriglyceridemia in patients
on HD, in the absence of PTH suppression [54].
In the studies using oral vitamin D3, the results are con-
ﬂicting [120]. Nevertheless, up to now there have been no
big trials concerning the impact of vitamin D3 therapy on
muscle mass. Therefore, the beneﬁcial, though indirect (by
insulin resistance improvement), eﬀect of such treatment re-
mains a hypothesis.
There is no doubt that the proper treatment of the met-
abolic acidosis accompanying chronic kidney disease may
inhibit the development of sarcopenia [121, 122]. In patients
with ESRD, an adequate dialysis leads to acidosis correction.
However, oral supplementation with NaHCO3 proved to be
eﬀective improving nutritional status and lean body mass.
The beneﬁts are probably caused by the impact on the UPS
system, reduced insulin resistance [123], and perhaps also
on increased activity of 1α-hydroxylase in the kidneys and
thereby increased synthesis of the active form of vitamin D
[54]. Pickering et al. in their study proved that using a di-
alysate with higher lactate concentration leads to decrease
in protein degradation most probably by downregulation
of UPS system. An increase in branched-chain amino acids
was also observed in the study. The study was conducted in
small group of patients, and the observation period was only
4w e e k s[ 123]. Though it conﬁrmed an earlier observations
made by Stein et al. of beneﬁcial inﬂuence of acid-base
balance correction in ESRD patients. In his group of 200
patients on peritoneal dialysis, the dialysate solution of
35mmol/l or 40mmol/l lactate contributed to higher serum
bicarbonates concentration. It was followed by weight gain
and increased muscle mass measured by mid-arm circum-
ference [122].
In patients with CKD in predialysis period, oral supple-
mentation of NaHCO3 was eﬀective in increasing DPI/DEI
as well as muscle mass (assessed by mid-arm circumference)
and serum albumin concentration [123, 124].
4. Conclusion
Sarcopenia is a common problem in patients with chronic
kidney disease. In those patients, a number of clinical prob-
lems have its origins much earlier than in healthy peers.
Sarcopenia also evolves much earlier than in the population
without chronic kidney disease, and its development is much
more rapid. It is associated with the whole-body protein-
energy deﬁciency called protein-energy wasting (PEW).
Sarcopenia,asanimportantelementofPEW,isthefactor
limiting patient’s autonomy as well as decreasing the quality
of life. If it cannot be treated with the simple methods
requiring some knowledge and devotion, we will fail to save
patients who die due to cardiovascular disease and infection,
despite proper conduction of renal replacement therapy.
Many factors inﬂuencing the risk of sarcopenia develop-
ment have been evaluated in a number of studies. The fact is,
however, that the arsenal for the prevention and treatment
still remains relatively poor. Although we know a lot of
hormonal and molecular mechanisms, in every day practice
we can safely apply the method, which has been successfully
used for many years in elderly people with or without kidney
disease: a proper nutrition to ensure an adequate intake of
calories and protein combined with skillfully matched and
regular exercise may act both as prevention and treatment.
In our center, there is no speciﬁc program for patients on
maintenance hemodialysis. We believe, that in terms of PEW,
everypatientshouldbetreatedindividuallydependingonhis
physical possibilities and expected eﬀects. Unfortunately, the
national health system in many countries does not support
such aspects of ESRD patients’ treatment. It seems, though,
that a fresh glance is required, as hemodialysis itself is not
enough for rescuing and improving patient’s life. There are
some conditions, which are necessary for hemodialysis to
become eﬃcient and successful. Patient’s nutrition and good
physical condition are the most important. Preventing and
treatment of PEW is undisputedly a way to keep the patient
in a good form.
Therefore, in our center we encourage the patients to
someaerobicphysicalactivity,whichshouldbeanelementof
every ESRD patient’s treatment. Progressive resistance train-
ing is possible for realization individually by the patient, as
there is no appropriate equipment in the dialysis center.
Physical activity should be supported by a proper dietary
protein intake. 1,5g protein/kg/24h should be a minimum
in patients on maintenance dialysis. It is worth to consider
even a higher dose of protein in patients on intensive exercise
treatment. Simple methods like implementing more meat
and eggs in the diet proved successful in the number of our
patients, who started to lose their lean body weight. The very
important feature of such a treatment is that it may be con-
tinued at home.
We have also got some experience with hormonal treat-
ment. One could summarize our attitude, that we let the
patients on hemodialysis do what is banned in competi-
tive sports: we givethem erythropoiesis-stimulating agents
(ESAs) and anabolic steroids [125].
Anabolic steroids proved to be eﬃcient in some of our
patients, especially in the group with ESA hypo-responsive-
ness and hemosyderosis. Although we ﬁnd a growth hor-
mone a valuable agent in PEW treatment, we have not used
it in our centre yet.
Megestrol acetate proved to be eﬃcient in people with
decreased appetite—it is worth to notice, that we have not
observed side eﬀects described in the literature so far.
In our center, we have also implemented a program for
patients with CKD in stage IV K/DOQI. In the number of
them, oral supplementation of NaHCO3 was introduced, re-
sulting in slower progression of the kidney disease into
ESRD. We have also noticed that such treatment may lead
to reduction of PEW symptoms in an early period after he-
modialysis initiation.
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